Urinary Tract Infections in Kidney Transplant Recipients : an Observational Cohort
试验速览
- 阶段
- 不适用
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Assessment of UTI due to MDR bacteria
研究概览
简要总结
The purpose of this study is to better estimate the prevalence of urinary tract infections (UTI) in kidney transplant (KIT) recipients, and especially multidrug resistant (MDR) bacteria. KIT recipients have a higher risk of UTI over the 6 first months following the transplantation. Urine culture was done in a city lab or at hospital. Current data on bacteriuria and candiduria lead mostly to hospital data that are incomplete..
详细描述
The risk of UTI after a kidney transplantation is higher than in the general population. MDR bacteria, such as extended spectrum betalactamase (ESBL)-producing enterobacteriaceae or MDR Pseumomoas aeruginosa are emerging threats due to antibiotic selective pressure. Epidemiological data are mostly data from hospital laboratories that do not show a complete overview of the current situation. In addition, the different centers which participated to this study received before the beginning of the study a protocol to avoid carbapenem use. The main objective of this study is to assess the prevalence of MDR bacteria in an adult population of KIT recipients. Through this study, the management of UTI in KIT recipients will be improved. Data on bacteria or yeasts responsible for UTI (identification, resistance profile), antibiotic use, patients' outcome, and graft outcome will be collected.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Assessment of UTI due to MDR bacteria
时间窗: Day 0 to 2 years
Proportion of MDR bacteria compared to other bacteria found in urinalysis of symptomatic KIT patients
次要结局
- Epidemiology of UTI in KIT recipients(Day 0 to 2 years)
- Carbapenem use to treat UTI(Day 0 to 2 years)
- Patients outcome(Day 0 to 2 years)
- Coherence between antibiotic protocol and treatment received to treat UTI(Day 0 to 2 years)
- Assessment of kidney function during the observation period(Day 0 to 2 years)
- UTI relapse frequency(Day 0 to 2 years)
- UTI recurrence frequency with a different micororganism(Day 0 to 2 years)
- Graft outcome(Day 0 to 2 years)
- Risk factors for MDR UTI(Day 0 to 2 years)